secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001326110-25-000138
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunityBio Q3 product revenue up 434% YoY to $31.8M; net loss narrows to $67.3M
--------------------------------------------------------------------------------

- Product revenue $31.8M in Q3 2025 vs $6.0M in Q3 2024; YTD sales $74.7M (+434%).
- ANKTIVA unit volumes up 467% YTD 2025 vs FY2024; net loss attributable to common $67.3M (vs $85.7M).
- Cash and securities $257.8M at Sep 30, 2025, up from $153.7M at Jun 30, 2025.
- Early glioblastoma combo study: 100% disease control (2 near-complete responses, 3 stable).
- Phase 3 NSCLC trial (ResQ201A) initiated; ANKTIVA named preferred drug by ~80M-life organization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000132611025000138/0001326110-25-000138-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000132611025000138/ibrx-20251104.htm
  HTML page:      https://secwatch.observer/filing/0001326110-25-000138

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer